Bobiao Ning

Bobiao Ning

Auto-generated profile, based on publicly available information

Bobiao Ning

The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2022 in Medicine
Verified
Journal Article
Open access
FYFan Yang
Fan Yang
YDYouzi Dong
Youzi Dong
BLBaohua Li
Baohua Li
BNBobiao Ning
Bobiao Ning
QZQuanlin Zhao
Quanlin Zhao
Background: Dipeptidyl-peptidase IV inhibitor (DPP-4i) is a common hypoglycemic medication in treating type 2 diabetes millitus. It has become widely utilized in clinical practice due to its ability to effectively manage blood glucose while posing a low risk of hypoglycemia and weight gain. However, there is no consensus on DPP-4i's pancreatic safety due to a paucity of clinical evidence. The safe event appears to be easily overlooked. This review aims to evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes mellitus using the standard pairwise and network meta-analysis methods. Methods: MEDLINE, Embase, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials will be used to search for published literature on the pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus, and clinical trial registries will be used to look for unpublished trials. Two independent reviewers will screen literature for eligibility, extract available data, and assess the risk of bias. All divergences will be resolved after rechecking the source papers and further discussion among the reviewers with a complete consensus before inclusion. The risk of bias will be assessed by the Cochrane bias risk tool, and the quality of evidence will be interpreted by the GRADE Working Group approach. We will use STATA16.0 and WinBUGS1.4.3 for paired meta-analysis and Bayesian network meta-analysis. Results: This study will evaluate the pancreatic safety of DPP-4 inhibitors in type 2 diabetes millitus. Conclusion: This systematic review and network meta-analysis will evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes millitus. The findings of this study may supplement the evidence-based information on DPP-4i, improve existing understanding of this issue, and assist patients and clinicians in making better treatment decisions by raising their awareness of the problem. Protocol registration number: INPLASY202230014.

15 November 2021 in Research Square
Verified
Preprint
Open access
PDF file
FYFan Yang
Fan Yang
QZQuanlin Zhao
Quanlin Zhao
YDYouzi Dong
Youzi Dong
BLBaohua Li
Baohua Li
BNBobiao Ning
Bobiao Ning
Background: Dipeptidyl-peptidase IV inhibitor (DPP-4i) is a common hypoglycemic medication in treating type 2 diabetes millitus (T2DM). It has become widely utilized in clinical practice due to its ability to effectively manage blood glucose while posing a low risk of hypoglycemia and weight gain. However, there is no consensus on DPP-4i's pancreatic safety due to a paucity of clinical evidence. The safe event appears to be easily overlooked. This review aims to evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes mellitus using the standard pairwise and network meta-analysis (NMA) methods.Methods: MEDLINE, Embase, Pubmed, Web of Science, and the Cochrane Central Register of Controlled Trials will be used to search for published literature and clinical trial registries (such as www.ClinicalTrials.gov) will be used to look for unpublished trials. English-language randomized controlled trials (RCTs) will be included. Two independent reviewers will screen literature for eligibility, extract available data, and assess the risk of bias. All divergences will be resolved after rechecking the source papers and further discussion among the reviewers with a complete consensus before inclusion. Pancreatic safety events involving acute pancreatitis, chronic pancreatitis, and pancreatic cancer will be the primary outcome. The secondary result will be the change in pancreatic enzyme from the baseline. A random-effects model will be used for pairwise meta-analysis with a 95% confidence interval, and Bayesian network meta-analysis will be conducted between the various interventions.Discussion: This systematic review and network meta-analysis will evaluate the pancreatic safety of DPP-4i in patients with type 2 diabetes millitus. The findings of this study may supplement the evidence-based information on DPP-4i, improve existing understanding of this issue, and assist patients and clinicians in making better treatment decisions by raising their awareness of the problem. Systematic review registration: submitted in PROSPERO, 31 August 2021